IPO
Summit Therapeutics plc reports its financial results and provides an update on its operational progress for the third quarter and nine months ended 31 October 2019.
Immuneering Corporation has announced the completion of a $17 million Series A financing.
Latest funding caps year of groundbreaking milestones for transformative vascular access company; new capital will be used to meet rapidly growing hospital and patient demand
AELIS FARMA, a biotechnology company specialized in the treatment of brain disorders, announces the completion of a €11 million financing round from the Region Nouvelle Aquitaine, Inserm Transfert Initiative, Bpifrance and the ACI, NACO and Aelis Innovation regional funds.
CELLINK’s goal is to grow sales organically with a minimum of 35% per year and grow additionally through acquisitions.
UK Innovation & Science Seed Fund, Catapult Ventures’ GM&C Life Sciences Fund and Jonathan Milner are pleased to announced an investment in Pencil Biosciences, a novel gene modulation company based at Alderley Park, Cheshire.
AQILION AB is selling its entire stake in the portfolio company Glactone Pharma AB to Daniel Lifveredson Invest AB.
StartX Med company Kodiak Sciences, a clinical stage company developing innovative therapeutics to treat high prevalence ophthalmic diseases, recently reached a market cap of $3.56 billion.
Recipharm, the contract development and manufacturing organisation, has invested USD 450,000 into its Research Triangle Park, North Carolina, US facility to install a SprayVIEW® system that will support inhalation and nasal product development.
Ardelyx, Inc. has announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $6.25 per share, before underwriting discounts and commissions, for gross proceeds of $125,000,000.
PRESS RELEASES